Epidemiological studies correlate moderate red wine consumption to reduced incidence of cardiovascular disease. Resveratrol is a polyphenolic compound in red wine that has cardioprotective effects in rodents. Although endothelial cell (EC) studies indicate that micromolar resveratrol has diverse biological activities, these concentrations are not physiologically relevant because human oral ingestion provides only brief exposure to nanomolar plasma levels. Previously, we reported that nanomolar resveratrol activated ERK1/2 signaling in bovine aortic ECs (BAECs). The goal of this study was to determine the mechanisms by which nanomolar resveratrol rapidly activates endothelial nitric oxide synthase (eNOS) in human umbilical vein ECs (HUVECs). We report for the first time that resveratrol increased interaction between estrogen receptor ␣ (ER␣), caveolin-1 (Cav-1) and c-Src, and increased phosphorylation of Cav-1, c-Src, and eNOS. Pretreatment with the lipid raft disruptor beta-methyl cyclodextrin or G␣ inhibitor pertussis toxin blocked resveratrol-and E 2 -induced eNOS activation and NO production. Depletion of endogenous ER␣, not ER␤, by siRNA attenuated resveratrol-and E 2 -induced ERK1/2, Src, and eNOS phosphorylation. Our data demonstrate that nanomolar resveratrol induces ER␣-Cav-1-c-SRC interaction, resulting in NO production through a G␣-protein-coupled mechanism. This study provides important new insights into mechanisms for the beneficial effects of resveratrol in ECs. Epidemiological studies have demonstrated that the consumption of polyphenolic-rich foods, i.e., fruits and vegetables, and drinking purple grape juice or moderate amounts of red wine reduces the incidence of mortality and morbidity from coronary heart disease and improves endothelial function (1). Regular, moderate intake of wine (0.7-1.1 oz/day) or alcohol (1.1-1.8 oz/day) has been reported to decrease coronary artery disease (2). A recent crossover study of 35 healthy premenopausal women found that two 100-ml glasses of red wine per day (20 g ethanol/day) for 4 wk resulted in a greater reduction in inflammatory biomarkers, cellular adhesion molecules (i.e., VCAM-1 and E-selectin), and monocyte adhesion to endothelial cells (ECs) compared to white wine (3). A key polyphenol implicated in the cardioprotective effects of red wine is trans-resveratrol, i.e., trans-3,5,4Ј-trihydroxystilbene (4). A study in healthy men of the oral absorption of 25 mg trans-resveratrol/70 kg administered in white wine, grape juice, and vegetable juice showed peak serum resveratrol concentrations of 40 nM, ϳ30 min after consumption (5). Notably, these serum levels are inconsistent with most reported cell-based studies in which the biological activities of resveratrol were detected between 5 and 100 M (5). However, circulating levels are consistent with our report that nanomolar resveratrol concentrations rapidly activated ERK1/2 (MAPK) in bovine aortic endothelial cells (BAECs) (6). Similar to estradiol (E 2 ) (7), MAPK activation by resveratrol was dependent on the activities of estrogen receptor (ER), MEK-1, c-Src, matrix metalloproteinases (MMPs), and epidermal growth factor-receptor (EGF-R), and, in turn, activated endothelial nitric oxide synthase (eNOS) (6). The resveratrol concentration that activated nongenomic/membrane-initiated ER signaling was an order of magnitude less than that required for ER genomic activity as we (8, 9) and others (10, 11) previously reported. These data coincide with the recent report that low doses (0.2 mg/kg/day) of a
ate amounts of red wine reduces the incidence of mortality and morbidity from coronary heart disease and improves endothelial function (1) . Regular, moderate intake of wine (0.7-1.1 oz/day) or alcohol (1.1-1.8 oz/day) has been reported to decrease coronary artery disease (2) . A recent crossover study of 35 healthy premenopausal women found that two 100-ml glasses of red wine per day (20 g ethanol/day) for 4 wk resulted in a greater reduction in inflammatory biomarkers, cellular adhesion molecules (i.e., VCAM-1 and E-selectin), and monocyte adhesion to endothelial cells (ECs) compared to white wine (3) . A key polyphenol implicated in the cardioprotective effects of red wine is trans-resveratrol, i.e., trans-3,5,4Ј-trihydroxystilbene (4) . A study in healthy men of the oral absorption of 25 mg trans-resveratrol/70 kg administered in white wine, grape juice, and vegetable juice showed peak serum resveratrol concentrations of 40 nM, ϳ30 min after consumption (5) . Notably, these serum levels are inconsistent with most reported cell-based studies in which the biological activities of resveratrol were detected between 5 and 100 M (5). However, circulating levels are consistent with our report that nanomolar resveratrol concentrations rapidly activated ERK1/2 (MAPK) in bovine aortic endothelial cells (BAECs) (6) . Similar to estradiol (E 2 ) (7), MAPK activation by resveratrol was dependent on the activities of estrogen receptor (ER), MEK-1, c-Src, matrix metalloproteinases (MMPs), and epidermal growth factor-receptor (EGF-R), and, in turn, activated endothelial nitric oxide synthase (eNOS) (6) . The resveratrol concentration that activated nongenomic/membrane-initiated ER signaling was an order of magnitude less than that required for ER genomic activity as we (8, 9) and others (10, 11) previously reported. These data coincide with the recent report that low doses (0.2 mg/kg/day) of a red wine polyphenolic extract (RWPC) were proangiogenic in postischemic rats, whereas high doses (20 mg/kg/day) were antiangiogenic (12) . E 2 has proven cardioprotective activity in animal models (13) . Estrogens have both genomic, i.e., transcriptional regulation, and "nongenomic," i.e., membrane-initiated intracellular signaling, activities mediated by direct binding to ER␣ and ER␤ (14) . Although nongenomic E 2 activity is mediated in part by GPR30 (15, 16) , E 2 does not activate MAPK in ECs from ER␣/ER␤ double-knockout (DERKO) mice (17) . Studies using carotid and femoral arteries isolated from ER␣-knockout (␣ERKO) and ER␤-knockout (␤ERKO) mice indicate that both ER␣ and ER␤ are responsible for E 2 -induced vasodilation (18) .
Cumulative studies show that a subpopulation of intact ER␣ is associated with the endothelial plasma membrane and with caveolae (13) . Recent electron microscopy studies revealed nuclear, cytoplasmic, and plasma membrane localization of both ER␣ and ER␤ in human umbilical vein ECs (HUVECs) (19) . Interestingly, there was no overlap of ER␣ and ER␤ immunofluorescent signals, indicating that ER␣ and ER␤ occupy discrete loci in HUVECs (19) . Thus, we propose that ER␣ and ER␤ may have different interaction partners and physiological effects in the vasculature, and the studies reported here address this hypothesis.
Caveolin-1 (Cav-1) serves as a structural core for interaction of plasma-membrane-associated proteins, including the ␣-subunit of G-proteins, Ha-Ras, Srckinases, eNOS, EGF receptors, some protein kinase-C isoenzymes (20) , and ER␣ (20, 21) . Binding of E 2 to ER␣ in caveolae leads to G␣i activation, MAPK and Akt signaling, and perturbation of the local Ca 2ϩ environment, leading to eNOS phosphorylation and NO production (13) . Endothelial plasma membrane-associated ER␣ is coupled via a G␣i to MAPK and eNOS (22) . Striatin couples ER␣ to G␣i in EAhy926 immortalized ECs (23) . The specific MEK inhibitor PD98059 blocked eNOS stimulation by E 2 in HUVECs (24) . Although no one has investigated endogenous ER␤-Cav-1 interaction in ECs, a recent study showed endogenous ER␤ bound to overexpressed Cav-1 in human embryonic kidney-293 cells, and this interaction resulted in E 2 -induced activation of MAPK, AP-1, and vitamin D receptor expression (25) . Lung tissue membranes isolated from ␤ERKO mice showed reduced levels of Cav-1, indicating a role for ER␤ in regulating Cav-1 expression (26). However, whether ER␣ and ER␤ differentially regulate the rapid, nongenomic effects of estrogens, including phytoestrogens that bind ER␤ with higher affinity than ER␣ (27) , in ECs remains to be addressed.
The goal of the experiments reported in this paper was to elucidate the components of the signaling pathways involved in the ability of nanomolar concentrations of resveratrol to increase eNOS activity through a MAPK-and ER-dependent (6) mechanism in ECs. Specifically, we addressed the roles of ER␣-and ER␤-caveolar interactions in the resveratrol-activated MAPKeNOS pathway in ECs. In this study, we tested the hypotheses that 1) resveratrol increases ER␣-and/or ER␤-Src-Cav-1 interaction, 2) resveratrol induces Cav-1 and eNOS phosphorylation, and 3) caveolae are required for rapid resveratrol-induced MAPK and eNOS activation. As described below, our results confirm the role of ER␣ in these interactions and reveal that ER␤ does not appear to play a role in the rapid signaling and interactions stimulated by either resveratrol or E 2 in HUVECs.
MATERIALS AND METHODS

Chemicals
E 2 , pertussis toxin (PTX), and methyl-␤-cyclodextrin (beta-CD) were from Sigma (St. Louis, MO, USA). ICI 182,780 and PP2 were purchased from Tocris (Ellisville, MO, USA). Transresveratrol was generously provided by Royalmount Pharma (Montreal, QC, Canada). E 2 and ICI 182,780 were dissolved in 100% ethanol (EtOH) and diluted in culture medium to a final 1:10,000 dilution (0.001% EtOH final).
Antibodies
Antibodies to Cav-1 and eNOS were obtained from BD Biosciences (San Jose, CA, USA); antibodies to Src, P-Tyr416-Src, P-Ser-118-ER␣, P-Tyr14-Cav-1, MAPK (ERK1/2), phospho-p44/42 MAPK(P-ERK1/2), P-Ser-1177-eNOS, P-Thr495-eNOS, AKT, and P-Thr308-AKT were obtained from Cell Signaling Technology (Beverly, MA, USA). ER␣ monoclonal antibody AER320 was obtained from Neomarkers/Lab Vision (Fremont, CA, USA). ER␤ polyclonal antibody H150 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ER␤ polyclonal PA1-311 and monoclonal MA1-32317 antibodies were purchased from Affinity BioReagents (Golden, CO, USA). ER␤ monoclonal antibody 6A12 (MS-ERB11-PX2) was from GeneTex (San Antonio, TX, USA).
Cell treatments
HUVECs were purchased from Cambrex BioScience (Walkersville, MD, USA), used between P3-8, and were maintained in EGM-2 (Cambrex). Cells were serum-starved for 24 h before each experiment and treated with vehicle (EtOH), 10 nM E 2 , 50 nM resveratrol, and other treatments, in EBM-2 medium without serum. Where indicated, cells were pretreated with 10 M PP2 for 1 h, 100 nM ICI 182,780 for 30 min, 100 ng/ml PTX for 17 h, or 5 mM beta-CD for 30 min before the addition of EtOH, 50 nM resveratrol, and 10 nM E 2 . The concentrations of the chemical inhibitors were selected to minimize off-target effects, based on published reports: PP2, the selective Src family kinase activity inhibitor (28); PTX, which inhibits G␣s and G␣i, but not G␣q (19) ; and methylbeta-CD, which disrupts caveolae by binding and sequestering cholesterol (29, 30) . HUVECs were treated with each inhibitor, e.g., PP2, ICI 182,780, beta-CD, and PTX, alone as well as in combination with EtOH, E 2 , or resveratrol, and cells were monitored by Brightfield microscopy. At the times and concentrations of each inhibitor used, there were no obvious changes in the morphology of the cells (Fig. 8) .
siRNA Mix) and Invitrogen (Carlsbad, CA, USA; ESR2 Stealth Select 3 RNAi). Control/nonspecific siRNA from each respective company was used in parallel with the ER subtype-specific siRNAs. The cells were transfected according to the manufacturer's protocols. Forty-eight hours post-transfection, the cells were treated with 10 nM E 2 , 50 nM resveratrol, or EtOH for 10 min, and whole cell extracts (WCEs) were harvested for Western blot analysis.
Measurement of NO
NO production was assessed using the NO-specific fluorescent dye 4,5-diaminofluorescein diacetate (DAF-2 DA; Sigma) (31) . In brief, HUVECs were incubated in serum-free EBM-2 medium with 100 M l-arginine (Sigma) for 24 h prior to loading with 3 M DAF-2-DA for 30 min at 37°C. Cells were rinsed 3ϫ with HEPES buffered physiological salt solution (PSS). Cells were then treated with EtOH, 10 nM E 2 or 50 nM resveratrol for 10 and 20 min. For the inhibitor studies, HUVECs were pretreated for 30 min with 100 M nitro-larginine methyl ester (L-NAME, Sigma), a NOS inhibitor; 5 mM beta-CD for 30 min, or 100 ng/ml PTX for 17 h before the cells were loaded with DAF-2 DA. After stimulation, the cells were fixed in 2% paraformaldehyde for 5 min at 4°C. The fixed cells were examined using a Zeiss Axiovert 200 inverted microscope (Carl Zeiss, Thornwood, NY, USA) with an ϫ10 objective lens, using an FL bulb and fluorescein isothiocyanate (FITC) filters with a peak excitation wavelength of 494 nm and a peak emission wavelength of 517 nm for DAF-2DA fluorescence. For Brightfield images, the light source was a halogen bulb and Brightfield filter in the same microscope. Images were captured using Axio Camera HRm and AxioVision Release 4.3 software (Carl Zeiss). All images were captured using identical microscope imaging settings with an exposure time of 236 s.
Preparation of WCEs, coimmunoprecipitation, and Western blot analysis
HUVECs were lysed in cold lysis buffer (10 mM Tris-HCl, pH 7.5; 10 mM NaCl; 0.5 mM EGTA; 1 mM EDTA; 1% Triton X-100; 1% Na cholate; 0.5 mM PMSF) supplemented with protease and phosphatase inhibitors (Sigma). Insoluble material was removed by centrifugation, and 150 g WCE was incubated with 1.5 g of caveolin-1 (Cav-1) antibody (BD Biosciences), ER␣, or ER␤ antibodies overnight (17 h) with rotation at 4°C. Protein A-Sepharose 4B (Zymed, San Francisco, CA, USA) was added for 2 h with rotation at 4°C. The beads were sedimented at 10,000 g and washed with lysis buffer 4ϫ, resuspended in 75 l of Laemmli buffer, and boiled; 30 l was separated on duplicate 10% SDS-PAGE gels and electroblotted onto polyvinylidene difluoride (PVDF) membranes (Pall Corporation, Pensacola, FL, USA) as described (6) . Membranes were probed first for phosphoproteins (P-ER␣, P-Src, P-Cav-1, P-eNOS) and then stripped and reprobed for ER␣, ER␤, Src, Cav-1, and eNOS. Mouse IgG TrueBlot (eBioscience, San Diego, CA, USA) was used as secondary antibody for some experiments. Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) was used to detect protein bands. Immunoblots were scanned into Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA, USA) using a Microtek ScanMaker III scanner (Microtek, Carson, CA, USA) and Un-Scan-It 5.1 (Silk Scientific, Orem, UT, USA) was used to digitize the data (6) . The treatmentspecific P-protein pixels were divided by concordant nonphosphoprotein pixels and by Cav-1 in the same blot. In all experiments, ratios of P-protein/total protein were normalized to EtOH, which was set to 1, to obviate any effect of the vehicle in which E2 and resveratrol were dissolved.
Statistical analysis
Statistical analyses were performed using Student's 2-tailed t test or 1-way ANOVA followed by Dunnett's multiple comparison with GraphPad Prism (GraphPad, San Diego, CA, USA). A value of P Ͻ 0.05 was considered statistically significant.
RESULTS
Resveratrol and E 2 induce ER␣-Cav-1 interaction and phosphorylation
Although resveratrol is a low-affinity agonist for genomic ER␣ and ER␤ activity (8 -11, 32-34) , no one has examined whether resveratrol affects ER␣-interaction with Cav-1 in ECs. Serum-starved HUVECs were treated with 50 nM resveratrol or 10 nM E 2 (positive control) for 2-30 min. Cellular proteins were immunoprecipitated with an antibody to Cav-1 and analyzed by immunoblotting with ER␣ and P-Ser-118-ER␣. Resveratrol increased ER␣-Cav-1 interaction with a peak at 5-20 min (Fig. 1A, B) . Similar results were observed for E 2 at the early time points, with a decrease in ER␣-Cav1 interaction at 30 min followed by a return to basal ER␣-Cav1 interaction by 45 min. Notably, the kinetics of direct ER␣-Cav-1 interaction in HUVECs was different in cells treated with E 2 or resveratrol at the 30-and 45-min time points. The E 2 data are in agreement with an E 2 -induced increase in ER␣-Cav-1 interaction in vascular smooth muscle cells (21) .
We examined whether the increase in ER␣-Cav-1 interaction triggered by resveratrol was associated with increased ER␣ phosphorylation on Ser-118, a target of MAPK (35) . Figure 1C -E shows that resveratrol and E 2 rapidly increased the amount of P-ER␣ associated with Cav-1 and increased the P-ER␣/ER␣ ratio. The amount of P-ER␣ associated with Cav-1 in resveratrol-treated HUVECs was increased between 5 and 30 min and then declined, with a second increase detected at 120 min. These data correlate with the ER␣/Cav-1 interaction data shown in Fig. 1A , B. Similar results were detected with E 2 . The ratio of P-ER␣/ER␣ after Cav-1 immunoprecipitation (IP) showed a different pattern with a peak at 5 min., followed by a decrease, and then resveratrol treatment resulted in a second peak at 20 min. (Fig. 1E ).
Resveratrol and E 2 induce Src-Cav-1 interaction and phosphorylation
Pretreatment of HUVECs for 6 h with 1 or 2.5 M resveratrol blocked subsequent VEGF-induced Src activation, Src-Cav-1 interaction, and Cav-1 phosphorylation (36) , but no one has examined the rapid effects of nanomolar concentrations of resveratrol on Src-Cav-1 interaction. Figure 2 shows that resveratrol and E 2 increased the amount of Src coimmunoprecipitated with Cav-1 by ϳ50% at the 5-min time point and that increased Src association with Cav-1 was sustained in resveratrol-treated HUVECs until after 20 min, whereas there was a decrease in Src-Cav-1 interaction at 10 min in E 2 -treated cells. Similarly, P-Tyr416-Src (active form of Src)-Cav-1 interaction peaked at 5 min in cells treated with either resveratrol or E 2 and then decreased. Phosphorylation of c-Src kinase on Tyr416 results in disruption of the inhibitory/inactive conformation due to intramolecular and intermolecular interactions between the SH2 domain and P-Y527 and between its SH3 domain and the SH2-kinase linker domains and allows molecular recognition of c-Src substrates and binding partners (37) . However, P-Src showed a second peak of interaction with Cav-1 at 20 min in resveratrol-treated cells. The ratio of P-Src/Src was increased after 2 min with either resveratrol or E 2 . The increase at the 20 min time point was not statistically significant. Pretreatment with the selective Src-kinase inhibitor PP2 blocked the increase in P-Src (Fig. 2D ).
Both resveratrol and E 2 increased the P-Cav-1/Cav-1 ratio at 10 and 120 min, indicating a biphasic effect on Cav-1 phosphorylation (Fig. 3A) . The data in Fig. 3B , C compare the time course of phosphoprotein-Cav-1 interaction in HUVECs after resveratrol or E 2 treatment. These data indicate different time kinetics of P-ER␣-Cav-1 interaction with resveratrol showing an extended P-ER␣-Cav-1 interaction compared to E 2 , which shows a peak at 5 min. Although the initial P-Src-Cav-1 peak at 5 min is similar for resveratrol and E 2 , resveratroltreated HUVECs show a second P-Src-Cav-1 peak at 20 min not seen in E 2 -treated cells. Figure 3B indicates that ER␣ in the ER␣-Cav-1 complex in resveratroltreated cells is maintained in the phosphorylated active form for an extended period of time, which may indicate that resveratrol has a sustained effect on e-NOS phosphorylation and NO production.
Resveratrol increases eNOS Ser-1177 phosphorylation
Phosphorylation of eNOS at Ser-1177 indicates activation, whereas P-thr495 indicates inactive eNOS Resveratrol and E 2 increase ER␣-Cav-1 and P-ER␣-Cav-1 interaction in HUVECs. Cells were treated with EtOH (control), E 2 (10 nM), or resveratrol (50 nM) for the indicated times. A) ER␣-Cav-1 interaction was examined by immunoprecipitation (IP) with an antibody to Cav-1 followed by immunoblotting with ER␣ antibody. The membrane was stripped and reprobed for Cav-1. Representative Western blots are shown. B) Quantitation of the relative ER␣/Cav-1 ratio with the t 0 ratio set to 1. C) Interactions of P-ER␣-Cav-1 and P-ER␣-ER␣ were examined by IP with an antibody to Cav-1 after 5 min of E 2 or resveratrol. D, E) Quantitation of the relative P-ER␣/Cav-1 (D) and P-ER␣/ ER␣ ratios (E) with the t 0 ratio set to 1. Values in B, D, and E are means Ϯ se from 3 separate experiments, except 60 min is from a single IP; *P Ͻ 0.05 vs. t 0 . (38) . The effect of resveratrol on eNOS phosphorylation is unknown. Here, we observed that resveratrol increased P-Ser-1177-eNOS in 5 min of treatment with a peak at 10 min for both resveratrol and E 2 ( Fig. 4A, B) . All data were normalized for the vehicle EtOH, which did not increase P-Ser-1177-eNOS (Fig. 4A , and data not shown for other time points up to 45 min). Wortmannin and PD98059 inhibited resveratrol-and E 2 -induced increase in P-Ser-1177-eNOS, indicating a role for both PI3K and MAPK pathways in eNOS activation. There was a concomitant decrease in P-thr495-eNOS after 10 min with resveratrol or cotreatment with E 2 or resveratrol and wortmannin. In contrast, cotreatment with PD958059 increased P-thr495-eNOS (Fig. 4C ). The increased P-Ser-1177-eNOS/eNOS at 5 and 10 min correspond to the time course of ER␣-Cav-1 interaction and Cav-1 phosphorylation. Resveratrol and E 2 increase phosphorylation of Cav-1, Src, and ER␣. HUVECs were treated with EtOH (control), E 2 (10 nM), or resveratrol (50 nM) for the indicated times. P-Cav-1-Cav-1, P-ER␣-Cav-1, P-Src-Cav-1 interactions were examined by IP with an antibody to Cav-1 as in Fig. 1. A) A representative Western blot at the 10-min time point for P-Cav-1/Cav-1. B, C) Quantitation of the P-ER␣/Cav-1, P-Src/Cav-1, and PCav1/Cav-1 ratios in resveratrol-treated (B) and E 2 -treated cells (C). Values are means Ϯ se from 3 separate experiments, except 60 min is from a single IP; *P Ͻ 0.05 vs. t 0 .
PTX blocks resveratrol-induced MAPK, Src, and eNOS phosphorylation E 2 stimulated the direct interaction of ER␣ with G␣i (22) via ER␣-striatin interaction (23) . To test the hypothesis that resveratrol's activation of Src, MAPK, and eNOS is mediated by G␣i, HUVECs were pretreated with PTX (Fig. 4D, E) . Pretreatment with PTX completely blocked resveratrol-and E 2 -stimulated Src, MAPK and eNOS activation, indicating that signaling involves PTX-sensitive G␣i or G␣s, but not G␣q (39) in HUVECs. Data are normalized to EtOH. Resveratrol did not act additively with E 2 in activating Src, MAPK, or eNOS, as measured by the phosphoprotein/total protein ratio (Fig. 4E) . Because we used individual concentrations of E 2 and resveratrol at which MAPK activation is maximum (6), we suggest that the lack of additivity indicates that the response is mediated by a common pathway which is saturated.
Pretreatment with ICI 182,780 inhibits recruitment of ER␣ to Cav-1 and Cav-1 phosphorylation
To test the role of direct resveratrol-ER␣ binding in the rapid changes observed in Figs. 1-3 , HUVECs were pretreated with 100 nM ICI 182,780 for 30 min before the addition of either 50 nM resveratrol or 10 nM E 2 . ICI 182,780 is a well-established antagonist of genomic ER that prevents coactivator recruitment (40) , inhibits ER␣ dimerization (41) , and enhances ER␣ proteasomal degradation after 6 h (40). In addition, ICI 182,780 inhibits the rapid E 2 activation of membrane-associated ER␣ responses (13, 42) but not GPR30-mediated activity (16) . Pretreatment of HUVECs with ICI 182,780 inhibited the resveratrol-and E 2 -induced increases in the P-Src/Src, P-Cav-1/Cav-1, P-ER␣/Cav-1 and ER␣/Cav-1 ratios (Fig. 5A, B) . These data indicate that the increased phosphoprotein/protein ratios and interactions induced by both resveratrol and E 2 are at least in part ERmediated.
Caveolae are required for resveratrol-induced ER␣-Cav1 interaction and eNOS activation
To determine whether caveolae are required for resveratrol-induced ER␣-Cav-1 interaction and phosphorylation of Src, Cav-1, and ER␣, serum-starved HUVECs were pretreated with EtOH (vehicle control) or 5 mM beta-CD for 30 min to disrupt caveolae by binding and sequestering cholesterol (29) . Figure 5C , D shows that beta-CD inhibited resveratrol-and E 2 -induced ER␣-Cav-1 interaction, and ER␣, Src, and eNOS-Ser-1177 phosphorylation.
Together, the results demonstrate that caveolae are required for Cav-1-ER␣-Src interaction and resveratrol signaling, and disruption of caveolae with beta-CD inhibits ER␣-Src-Cav-1 interaction and resveratrol-and E 2 -induced ER␣ phosphorylation and eNOS activation.
Resveratrol and E 2 do not stimulate ER␤-Cav-1 interaction
No one has examined the effect of E 2 or resveratrol on endogenous ER␤-Cav-1 interaction and downstream sig- Resveratrol and E 2 activate eNOS in a wortmannin-, PD98059-, and PTX-sensitive manner. A-C) HUVECs were treated with EtOH, E 2 (10 nM), or resveratrol (50 nM) for the indicated times. Where indicated, HUVECs were pretreated with 100 nM wortmannin (Wort) or 50 M PD98059 for 1 h prior to 10 min treatment with EtOH, resveratrol, or E 2 . WCEs were analyzed with anti-Ser-1177-eNOS (active eNOS; A, B), or anti-P-thr495-eNOS antibody (inactive eNOS; C). D, E) HUVECs were pretreated with 100 ng/ml PTX for 18 h prior to a 10 min treatment with EtOH, 10 nM E 2 , or 50 nM resveratrol. WCEs were analyzed using Western blot analysis with P-MAPK, P-Src, P-Ser-1177-eNOS antibodies, and reprobing the same blots for MAPK, Src, or e-NOS. Three representative Western blots are shown. Graphs show quantitation of the P-Ser-1177-eNOS/e-NOS (B), P-thr-495-eNOS/eNOS (C), and P-protein/protein ratios (E). Values are means Ϯ se from 3 separate experiments; *P Ͻ 0.05 vs. EtOH; † P Ͻ 0.05 vs. same treatment without Wort or PD98059 (B) or PTX pretreatment (E).
naling pathways in ECs. Quantitative Western blot analysis using recombinant human (rh) ER␣ and ER␤ as standards revealed that HUVECs express 0.9 and 0.2 fmol/g WCE protein of ER␣ and ER␤, respectively (data not shown). Thus, HUVECs have ϳ4.5 times more ER␣ than ER␤. ER␤ was shown to immunoprecipitate with Cav-1 (Fig. 6A) . Because ER␤ and some of its splice variants migrate ϳ53-59 kDa, Mouse IgG TrueBlot, which has low reactivity with mouse IgG heavy and light chains (55 and 23 kDa), was used to demonstrate the specificity of ER␤ signal detection. In contrast to ER␣, neither resveratrol or E 2 increased ER␤-Cav-1 interaction (Fig. 6A) . Similar results were obtained using ER␤ polyclonal antibodies H150 and PA1-311 (data not shown). In reverse IP experiments in which HUVEC WCEs were immunoprecipitated with ER␤ and probed for Cav-1, the Cav-1/ER␤ ratio decreased with a 10-min treatment of either resveratrol or E 2 (Fig. 6B) . Although ER␣ and ER␤ form homodimers and heterodimers in isolated plasma membrane preparations from HUVECs (17), ER␣ did not coimmunoprecipitate with ER␤ (Fig. 6B ). The band detected at ϳ54 kDa is IgG heavy chain (Fig. 6B) . Thus, E 2 or resveratrol decreased ER␤-Cav-1 interaction (Fig. 6C) , in contrast to the increased ER␣/Cav-1 ratio with E 2 and resveratrol (Fig. 1B) . In conclusion, although both ER␣ and ER␤ interact with Cav-1 in HUVECs, resveratrol and E 2 appear to have opposing effects on ER␣-and ER␤-Cav-1 interaction.
Knockdown of ER␣ and not ER␤ inhibits rapid activation of MAPK, Src, and eNOS by E2 and resveratrol
To further examine the ER subtype specificity for the observed rapid stimulation of MAPK, Src, and eNOS phosphorylation in response to resveratrol and E 2 in HUVECs, cells were transfected with control/nonspecific siRNA or siRNA targeting ER␣ or ER␤. Transfection of HUVECs with siRNA for ER␣ reduced ER␣ protein by 80% but had no significant effect on ER␤ expression (Fig. 7A) . Transfection of HUVECs with siRNA for ER␤ reduced ER␤ protein by 75%, but had no significant effect on ER␣ expression (Fig. 7B) . Knockdown of ER␣ reduced the E 2 -or resveratrolinduced activation of MAPK, Src, and eNOS, as well as basal eNOS phosphorylation (Fig. 7C) . In contrast, knockdown of ER␤ did not significantly inhibit the E 2 -or resveratrol-induced activation of MAPK, Src, or eNOS. Together, these data indicate that ER␣, not ER␤, plays the major role in the E 2 -and resveratrolinduced activation of MAPK, Src, and eNOS in HUVECs.
Resveratrol stimulates NO production
We examined the acute effects of resveratrol and E 2 on NO production using DAF-2 fluorescent dye. Resveratrol-and E 2 -induced DAF-2 fluorescence, indicative of NO production, was maximal after 10 min and was sustained after 20 min (Fig. 8) . To verify that the increase in green fluorescence reflected NO production, HUVECs were pretreated with L-NAME, a NOS inhibitor. As expected, L-NAME blocked the increase in green fluorescence. Pretreatment of HUVECs with beta-CD and PTX also completely blocked resveratrolor E 2 -induced NO production (Fig. 8) . These data agree with resveratrol-induced Ser-1177 eNOS phosphorylation (Fig. 4A) . 
DISCUSSION
Red wine and its key constituent resveratrol have a variety of activities associated with cardioprotective effects (2) . Nonetheless, the exact mechanisms for red wine's ability to prevent coronary artery disease and stroke is not fully elucidated. One major area of concern in studying resveratrol's effects is the discrepancy between the high concentrations apparently needed to achieve biological activities in vitro or in animal models with the epidemiological effects seen at moderate red wine consumption that would achieve only nanomolar or lower concentrations of bioactive polyphenolics in vivo for a short time (5) . The primary goal of this study was to determine the molecular mechanisms by which nanomolar concentrations of resveratrol, concentrations compatible with oral consumption (5), rapidly activate NO production in ECs by examining endogenous rather than overexpressed proteins. Here, we demonstrated that nanomolar concentrations of resveratrol, like E 2 (43), increase ER␣-Cav-1-Src interaction in lipid rafts/caveolae in HUVECs in a timedependent manner leading to Cav-1, Src, ERK1/2, and eNOS phosphorylation, and NO production. Furthermore, we show that resveratrol's activation of eNOS appears to be mediated by activation of G␣i and/or G␣s proteins and that ER␤ does not appear to be critical for these signaling events, since siRNA knockdown of ER␤ did not prevent resveratrol or E 2 activation of Src, MAPK, or eNOS in HUVECs. Previously, we reported that nanomolar concentrations of resveratrol activated NO production in BAECs in an ER-, Src-, MEK1/ERK1/2-, MMP-, and EGF-Rdependent manner (6) . However, the exact mechanisms by which resveratrol-ER interaction activated eNOS remained undefined. ER␣ localizes in caveolae of ECs (13) , and the signal transduction mechanisms by which E 2 rapidly (i.e., nongenomically) activates eNOS have been explored (reviewed in ref. 44) . ER␣ interacts directly with c-Src, Cav-1, hsp90, and other proteins in caveolae of ECs and breast cancer cells (13, 20, (45) (46) (47) . In response to E 2 , Src is rapidly activated, inducing formation of a complex that contains ER␣, c-Src, and the p85 subunit of PI3K. These interactions are required for activation of eNOS (13, 42, 43) . Our data are consistent with these reports, as we demonstrated that resveratrol, like E 2 , rapidly induces ER␣-Cav-1 association, whereas neither resveratrol nor E 2 stimulates ER␤ interaction with Cav-1 interaction. Resveratrol, like E 2 (43, 48) , increased ER␣ and ER␤ interaction with c-Src. Further, our data showing that ER␣ did not coimmunoprecipitate with ER␤, and vice versa, is also consistent with recent electron microscopy studies indicating that (lanes 1-3) , and WCEs (150 g protein) were immunoprecipitated with Cav-1 followed by immunoblotting with ER␤ monoclonal antibody 6A12 and Cav-1. These membranes used mouse IgG TrueBlot HRP-conjugated secondary antibody to minimize interference by the heavy and light chains of the immunoprecipitating antibody, as described in Materials and Methods. For lane 4, Cav-1 antibody was incubated with protein A-sepharose 4B overnight, rinsed with lysis buffer, and boiled in Laemmli buffer, as described in Materials and Methods. Laemmli buffer (25 l) was loaded in lane 4; Cav-1 antibody (0.5 g) was diluted in Laemmli buffer, boiled, and loaded into lane 5. Lanes 6 and 7 include 15 g WCEs from EtOH-or E 2 -treated HUVECs, respectively. Baculovirus-expressed rhER␤ (14 fmol) was included as a control (lane 8). B) Reverse IP: ER␤-Cav-1 interaction was examined by IP (as in A) with an antibody to ER␤ antibody (MA-23217, lanes 1-3) and Western blot analysis for Cav-1. Baculovirus-expressed rhER␣ (558 and 1395 fmol, lanes 4 and 5) or rhER␤ (355 and 710 fmol, lanes 6 and 7) were separated in parallel. Molecular weight (MW) marker size is indicated in kilodaltons. Antibody specificity is demonstrated: ER␤ antibody H150 did not recognize ER␣ and ER␣ antibody AER320 likewise did not bind ER␤. C) Quantitation of the ER␤/Cav1 and Cav-1/ER␤ ratios from 3 separate experiments for each IP (IP-Cav-1, probe ER␤; IP-ER␤, probe Cav-1). Values are means Ϯ se[scap]; *P Ͻ 0.05 vs. EtOH (Student's t test, 2-tailed). D) Western blot for ER␣ in WCEs of HUVECs: 40 g WCE from MCF-7 (untreated) or HUVECs, untreated, or treated for 10 min with EtOH, 10 nM E 2 or 50 nM resveratrol, was separated on a 10% SDS-PAGE gel. The indicated amount (fmol) of rhER␣ was added as a loading control. MW marker size is indicated in kilodaltons. The membrane was first probed with AER320 ER␣ antibody and then stripped and reprobed for ␣-tubulin. There is no evidence of the ϳ54 kDa band detected by AER320 in the IP for ER␤ in B. We suggest that this is mouse IgG.
ER␣ and ER␤ occupy discrete loci in HUVECs (19) . Thus, we conclude that ER␣ and ER␤ have different interaction partners in HUVECs and speculate that this may apply to physiological interactions in the vasculature as well. Support for this idea at the genomic level is borne out by recent microarray profiling of genes regulated by E 2 in aortas from ovariectomized wild-type vs. ER␣ or ER␤ knockout mice (49) . ER␣ was responsible for the up-regulation of most of the identified E 2 target genes in the aorta. In contrast, E 2 -ER␤ actively repressed the transcription of nuclear-encoded mitochondrial respiratory chain genes. Because the animals were treated for 1 wk with E 2 , these data reflect not only primary target genes, but secondary and tertiary genes as well as integration of nongenomic and genomic actions of E 2 in the aorta. That ER␣ and ER␤ have selective actions in a cell-type-dependent manner is likewise indicated by the report that E 2 and genistein, a phytoestrogen that is a selective ER␤ agonist, but not propyl-pyrazole-triol, a selective ER␣ agonist, increased eNOS and decreased nNOS at the mRNA and protein levels in the rat hypothalamic paraventricular nucleus (50) . Moreover, the ER␤-selective agonist diarylpropionitrile rapidly increased NO production, and E 2 -stimulated NO was inhibited by the selective ER␤ antagonist R,R-tetrahydrochrysene (51) . In addition to E 2 and synthetic ER ligands, a variety of phytochemicals and endocrine disruptors initiate second messengertriggered signal cascades emanating from the plasma membrane that are mediated by ER␣, ER␤, and/or GPR30 (52) (53) (54) (55) (56) (57) .
One novel finding in the present study is that nanomolar levels of resveratrol, like E 2, caused a rapid association of Cav-1 with Src (Fig. 2B) . However, resveratrol elicited a more sustained interaction (5-20 min), whereas E 2 caused only transient interactions peaking at 5 and 20 min. Indeed, the chronological order of protein-protein interactions and phosphorylation stimulated by resveratrol and E 2 , while largely overlapping, is somewhat different (Fig. 3B, C) . For example, E 2 more rapidly increased ER␣-Cav-1 interaction compared to resveratrol (Fig. 1B) . Further, the E 2 -induced ER␣-Cav-1 interaction was reduced below basal at 30 min, whereas the resveratrol-activated interaction was reduced at 45 min. The mechanism for the differences in chronology and the more sustained Cav-1-Src triggered by resveratrol interaction is unknown but may involve differences in the identity or kinetics of proteins in addition to those tested here and that are involved in the signalosome complex, such as MNAR/PELP and the p85 regulatory subunit of PI3K (58) . Further studies are required to identify the proteins involved in differences between resveratrol and E 2 . Importantly, Src kinase activity appears to be involved in resveratrol-and E 2 -induced eNOS activation, since pretreatment with the selective Src kinase inhibitor PP2 completely blocked resveratrol-or E 2 -induced association of Src/Cav-1 (Fig. 2D) . These data are consistent with previous reports on E 2 activation of the Src-Cav-1-eNOS signaling pathway in rat lung ECs and MCF-7 human breast cancer cells (21, 59) .
Another novel observation is that the rapid effects of resveratrol are mediated by Cav-1-associated full-length ER␣ (66 kDa). Although the 46-kDa isoform of ER␣ lacking the N terminus (A and B domains) was reported to be preferentially associated with the plasma membrane in EA.hy926 cells (immortalized human ECs) (37, 60) , our data show that full-length ER␣ and ER␤1 (61) were immunoprecipitated with Cav-1 in HUVECs. It is possible that the ER␣ isoforms present in the plasma membrane differ in different ECs. Notably, pretreatment with ICI 182,780 before the addition of resveratrol or E 2 and siRNA against ER␣, not ER␤, blocked the P-Src/Src, P-Src/Cav-1, P-Cav-1/Cav-1, P-ER␣/ER␣, P-ER␣/Cav-1, and ER␣/Cav-1 interactions (Fig. 5B) and phosphorylation of Src, Cav-1, eNOS, and ER␣ (Fig. 7) .
Cumulatively, our data suggest that resveratrol and E 2 activate a similar nongenomic ER pathway (Fig. 9 ) that accounts for rapid E 2 activation of eNOS in ECs (22, 43, 45, 46) . In contrast to our previous study in BAECs in which subtype-specific ligands indicated roles for both ER␣ and ER␤ in eNOS activity (6) , siRNA knockdown studies in HUVECs indicate that ER␣ plays a predominant role in the resveratrol and E 2 -activation of MAPK, Src, and eNOS. Coincidentally, while resveratrol and E 2 increased ER␣-Cav-1 interaction within 5 min, ER␤-Cav-1 interaction was decreased by ligand treatment (Fig. 6) . Thus, it is tempting to speculate, on the basis of numerous studies in a variety of tissues/cell types establishing that ER␤ is a down-regulator of responses up-regulated by ER␣ (62) (63) (64) (65) (66) (67) (68) (69) (70) (71) , that the decrease in ER␤-Cav-1 interaction may be part of the stimulatory mechanism.
Cav-1 is a substrate for Src kinase that phosphorylates Cav-1 on Tyr-14 (72) . Increased P-Cav-1 has been suggested as an indicator of a reduced interaction between Cav-1 and other signaling proteins (20) . Our data agree with these findings, as indicated by the inverse association of Cav-1 phosphorylation, i.e., at 10 min, with reduced P-Src-Cav-1 and P-ER␣-Cav-1 association. However, when P-Cav-1/Cav-1 peaked again at 60 min and remained high up to 120 min in resveratroltreated cells, P-ER␣/Cav-1 was also high (Fig. 3B ). The distinct difference between E 2 and resveratrol induced effects in HUVECs is the extended P-ER␣-Cav-1 association in resveratrol-, but not E 2 -treated cells (Fig. 3C) . Notably, beta-CD, which disrupts caveolae-like structures by binding to and sequestering cholesterol from the plasma membrane of intact cells (73) , abolished resveratrol-and E 2 -induced protein-Cav-1 associations, eNOS phosphorylation, and NO production. These observations indicate that intact caveolar structure is required for resveratrol's rapid effects on ER␣-Cav-1 interaction, eNOS activation, and NO production in HUVECs, similar to our observations reported here using E 2 as a positive control established in ECs by other investigators (13, 20) .
Because direct interactions between plasma membrane-associated ER␣ and G␣i have been implicated in Figure 9 . Signaling pathways by which resveratrol rapidly activates eNOS and increased NO production in HUVECs. Resveratrol, like E 2 , activates ER␣ that is localized in a "signalsome complex" within caveolae that includes Cav-1, which binds Src, Grb7, MEK, G proteins, and eNOS (47, 82) . This model is based primarily on studies in breast cancer cells and BAECs from E. Levin's group (7, (82) (83) (84) (85) and our present and previously reported research (6) . Data reported here indicate that ER␤-Cav-1 interaction is reduced by E 2 and resveratrol, suggesting the possibility that ER␤ leaving the plasma membrane may be part of the stimulatory mechanism leading to downstream phosphorylation events and NO production. Chemicals that inhibit the activity of steps in the pathway used in experiments reported here are indicated. Resveratrol and E 2 increase NO production in HUVECs. HUVECs were serum-starved and loaded with DAF-2 DA before treatment with EtOH, 10 nM E 2 , or 50 nM resveratrol for 10 or 20 min, as indicated. Where indicated, cells were pretreated for 30 min with 100 M l-NAME or 5 mM ␤-CD, or for 17 h with 100 ng/ml PTX. Cells were fixed and viewed as described in Materials and Methods. Emission of green light (510 nm) from cells excited at 480 nm is indicative of NO production. Scale bars ϭ 100 m.
eNOS activation and NO production in COS-7 cells transfected with ER␣ and specific G␣i proteins (22), we investigated whether G␣i is involved in resveratrolinduced e-NOS activation in HUVECs. Our data demonstrate that pretreatment with PTX, a G␣ inhibitor, blocked completely resveratrol's activation of Src, MAPK, and eNOS, indicating that G␣ plays an important role in rapid resveratrol signaling in HUVECs. These findings are similar to E 2 as shown here and reported by others (13, 20, 44, 74) .
Previous studies showed that high concentrations (micromoles or even millimoles) of resveratrol have a variety of beneficial activities in cardiovascular tissues (75) . For example, 10 M resveratrol produced a powerful relaxation response in endothelium-containing rings of rat aorta (76) . Likewise, 10 M resveratrol caused rapid coronary vasodilation and increased coronary flow in Langendorff-perfused rat hearts (77) . Recently, a 5-min treatment with 30 or 100 M resveratrol suppressed ischemia-reperfusion-induced ventricular arrhythmias in perfused rat hearts (78) . These studies are limited by nonphysiologically relevant resveratrol concentrations used (5) . In addition to differences in resveratrol effects due to high concentrations used experimentally, we hypothesize that because of its rapid metabolism (79 -81), resveratrol's acute effects in the vasculature may contribute to its vascular/cardioprotective effects through different mechanisms than chronic/high dose effects. The resveratrol concentration used here is an order of magnitude less than that required for ER genomic activity as reported by us (8, 9) and others (10, 11) .
In conclusion, the data presented here demonstrate that nutritionally relevant (nanomolar) concentrations of resveratrol rapidly activate plasma membrane-associated ER␣ in caveolae of HUVECs, leading to eNOS activation and NO production via activation of G␣i, Cav-1, Src, and MAPK in a manner similar to that elicited by E 2 . These studies imply that dietary intake of resveratrol may offer possible vascular protective effects in vivo.
